LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against KemPharm, Inc. (“KemPharm” or the “Company”) (Nasdaq: KMPH) concerning possible violations of federal securities laws.
To get more information about this investigation, click here, or please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.
KemPharm submitted a New Drug Application to the U.S. Food and Drug Administration ("FDA") for their Apadaz product, intended to be marketed as an "abuse-deterrent" opioid that offers the same effectiveness as existing standard-of-care products, but with less of an addictive effect.
On May 5, 2016, KemPharm revealed that the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the FDA had reviewed and voted against including an abuse-deterrent label for Apadaz. The FDA cited an issue with the study design of Apadaz making it difficult to use in measuring the abuse-deterrent effect of the drug.
When this news was released to the public, the value of KemPharm dropped, causing investors harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.